Approval · Notice of Compliance 32804 · 2024
NAT-BENDAMUSTINE: Notice of Compliance 32804
Issued February 29, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32804
- Date
- February 29, 2024
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Control of drug product: change in the specification for the drug product
- Canadian reference product
- TREANDA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-BENDAMUSTINE | 02496895 | Marketed |
| NAT-BENDAMUSTINE | 02496887 | Marketed |
Medicinal ingredients
- BENDAMUSTINE HYDROCHLORIDE 100 MG per VIAL
- BENDAMUSTINE HYDROCHLORIDE 25 MG per VIAL